Asceneuron Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 18
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.2M
Latest Deal Amount
  • Investors
  • 7

Asceneuron General Information

Description

Developer of therapeutic drugs designed for debilitating neurodegenerative disorders with unmet medical need. The company's drugs aids to address diseases such as orphan tauopathies, Alzheimer's and Parkinson's diseases and also specializes in the discovery and development of groundbreaking small molecule therapeutics for neurodegenerative diseases, enabling patients to radically improve the quality of life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Services
Primary Office
  • EPFL Innovation Park
  • Bâtiment B
  • 1015 Lausanne
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Asceneuron Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 09-Mar-2021 $2.2M 000.00 Completed Generating Revenue
4. Early Stage VC (Series A) 29-Sep-2015 000.00 000.00 Completed Generating Revenue
3. Grant 09-Apr-2015 00000 00.000 Completed Startup
2. Seed Round 02-Oct-2012 $6.44M $6.44M Completed Startup
1. Accelerator/Incubator Completed Startup
To view Asceneuron’s complete valuation and funding history, request access »

Asceneuron Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic drugs designed for debilitating neurodegenerative disorders with unmet medical need. The compan
Drug Discovery
Lausanne, Switzerland
18 As of 2021
000.00
0000000000 000.00

00000 00

exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repr
0000000000000
Philadelphia, PA
000 As of 0000
00000
0.000 0000-00-00
000000&0 00000

000000 0

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore
0000 000000000
Cambridge, MA
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asceneuron Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spark Therapeutics Formerly VC-backed Philadelphia, PA 000 00000 000000&0 00000
000000 00000000000 Venture Capital-Backed Cambridge, MA 00 000.00 000000&0 000.00
00000000 000000000 Formerly VC-backed San Francisco, CA 000 00000 000000&0 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 0000000000 000.00
0000 Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
You’re viewing 5 of 32 competitors. Get the full list »

Asceneuron Executive Team (6)

Name Title Board Seat Contact Info
Dirk Beher Ph.D Co-Founder, Chief Executive Officer & Board Member
Bruno Permanne Ph.D Head, Biology
Anna Quattropani Ph.D Head of Non-Clinical Development and Medicinal Chemistry
J. Michael Ryan MD Chief Medical Advisor
You’re viewing 4 of 6 executive team members. Get the full list »

Asceneuron Board Members (14)

Name Representing Role Since
Deborah Harland Ph.D SR One Board Member 000 0000
Dirk Beher Ph.D Asceneuron Co-Founder, Chief Executive Officer & Board Member 000 0000
Eric Yuen MD Self Board Member 000 0000
Franz Hefti Ph.D Self Board Member 000 0000
Hakan Goker Ph.D M Ventures Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Asceneuron Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asceneuron Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Johnson & Johnson Innovation - JJDC Corporate Venture Capital Minority 000 0000 000000 0
Kurma Partners Venture Capital Minority 000 0000 000000 0
Sofinnova Partners Venture Capital Minority 000 0000 000000 0
SR One Corporate Venture Capital Minority 000 0000 000000 0
Alzheimers Drug Discovery Foundation Not-For-Profit Venture Capital 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »